RBC said it was highly likely that the FDA will allow Sarepta's (SRPT) drug Elevidys for Duchenne muscular dystrophy to remain on the market.
https://seekingalpha.com/news/4043108-rbc-sees-sareptas-elevidys-remaining-on-market-report
RBC said it was highly likely that the FDA will allow Sarepta's (SRPT) drug Elevidys for Duchenne muscular dystrophy to remain on the market.
https://seekingalpha.com/news/4043108-rbc-sees-sareptas-elevidys-remaining-on-market-report
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.